Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Researchmoz added Most up-to-date research on "Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation" to its huge collection of research reports.

Asthma is a chronic condition affecting the respiratory system, with disease occurrence linked to both genetic and environmental factors. It has significant global incidence and there is currently no cure. Pharmacotherapeutic intervention aims to provide patients with an increased level of disease control and reduce the severity of symptoms, and a number of inhalational therapeutic options are available.

Current asthma treatment options are able to provide the majority of patients with a sufficient level of disease control. Additionally, scientific advancements through the development of combination and add-on therapeutics have provided patients with treatments that allow for a greater level of disease control. However, unmet need remains, in the form of patients that do not respond well to current therapeutics or therapeutic combinations. This group of patients accounts for the vast majority of global healthcare costs associated with asthma. Pipeline product development aims to improve upon current therapeutic options and provide options for satisfactory disease control to patients with unmet needs. This is reflected in the high number of products in development, with 287 pipeline products, accounting for just over a third of products within the broader respiratory therapy area pipeline.

There are a total of 93 first-in-class pipeline products in development for asthma, representing a substantial 44% of the 212 pipeline products for which there is a disclosed molecular target.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=879380

A number of these first-in-class pipeline programs appear to have significant potential to strengthen the asthma treatment landscape – as well as representing promising commercial opportunities. A large number of first-in-class products in the current asthma pipeline have not previously been involved in licensing or co-development deals. This highlights the significant opportunities in the asthma pipeline, and the many possibilities for high-risk, high-reward investment.

Scope

• Analysis of innovation in the asthma market in the context of the overall pipeline and current market landscape – also includes analysis of the deals landscape surrounding first-in-class products in asthma, and highlights opportunities for in-licensing
• A brief introduction to asthma, including symptoms, pathophysiology, and an overview of pharmacotherapy
• The changing molecular target landscape between the market and the pipeline, and particular focal points of innovation in the pipeline
• Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target
• Identification and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets
• Assessment of the licensing and co-development deal landscape for asthma therapies, and benchmarking of deals involving first-in-class versus non-first-in-class-products

Browse TOC @ https://www.researchmoz.us/frontier-pharma-asthma-therapeutics-cytokine-and-kinase-targeted-small-molecules-and-mabs-increase-pipeline-diversity-and-dominate-firstinclass-innovation-report.html/toc

Reasons to buy

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment strategies currently available.
• Visualize the composition of the asthma market in terms of the dominant classes of therapies. Unmet needs are highlighted to allow a competitive understanding of current gaps in the market.
• Analyze the asthma pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target. There are signs in the pipeline that the industry is seeking novel approaches to meet unmet needs within asthma.
• Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
• Identify commercial opportunities in the asthma deals landscape by analyzing trends in licensing and co-development deals and assessing asthma therapies that are not yet involved in deals, and may be potential investment opportunities.

U.S. and China Asthma and COPD Drugs Market From 2016 – 2024: Development of New Biologics to Combat Respiratory Diseases to Provide Strong Impetus

Researchmoz added Most up-to-date research on "U.S. and China Asthma and COPD Drugs Market From 2016 – 2024: Development of New Biologics to Combat Respiratory Diseases to Provide Strong Impetus" to its huge collection of research reports.

U.S. and China Asthma and COPD Drugs Market: Overview

Asthma is a disease characterized by recurrent attacks of coughing, chest-tightening, breathlessness, and wheezing as the airways narrow and swell that vary in severity and frequency. COPD is a disease of the lungs characterized by obstruction to airflow that interferes with normal breathing. According to the WHO, COPD accounted for over 3 million deaths in 2012, which is equal to 6% of all deaths globally in that year. Moreover, the WHO predicts that COPD will become the third most common cause of death globally by 2030. However, these statistics have already materialized in the U.S. and China, where COPD is currently said to be the third leading cause of mortality.

According to the Asthma and Allergy Foundation of America, asthma is the leading chronic disease in children in the U.S. It is also the most common reason for missed school days. Moreover, an estimated 10 people in the U.S. die from asthma each day, while 3,630 die each year. In China, the figures are worse. A large population of COPD patients goes underdiagnosed or misdiagnosed in China every year. A large proportion of these deaths are avoidable with proper treatment and care. Thus, the existence of an unmet medical need is clearly evident and is anticipated to augment the asthma and COPD drugs market.

U.S. and China Asthma and COPD Drugs Market: Scope and Methodology
This report on the asthma and COPD drugs market in the U.S. and China analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market related factors such as technological developments, patent expiry, recent drug approvals, investment in clinical studies and acquisitions by leading players in the market, and historical year-on-year growth have been taken into consideration while estimating the market size.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=893048

Growth rates for each segment within the U.S. and China asthma and COPD drugs market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, drug development life cycle, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the asthma and COPD drugs market in the U.S and China.

U.S. and China Asthma and COPD Drugs Market: Segmentation
Based on drug class, the asthma and COPD drugs market in the U.S and China has been segmented into bronchodilators, anti-inflammatory drugs, monoclonal antibodies, and combination drugs. The bronchodilator class has been further segmented into short acting beta-2 agonists, long acting beta-2 agonists, and anti-cholinergic agents. The anti-inflammatory drug class has been further segmented into oral and inhaled corticosteroids, anti-leukotrienes, phosphodiesterase type 4 inhibitors, and others. The others segment includes mast cell stabilizers and other anti-inflammatory agents used in asthma and COPD control.

Based on indication, the asthma and COPD drugs market in the U.S. and China has been segmented into asthma and COPD. According to the CDC, one in 12 people in the U.S. has asthma, and the number is rising each year. Pollution in China is among the worst in the world. This is likely to worsen asthma and COPD symptoms, consequently driving the asthma and COPD market in China during the forecast period.

Geographically, the asthma and COPD market has been segmented into two countries: the U.S. and China. These countries have been further segmented by indication and drug class.

U.S. and China Asthma and COPD Drugs Market: Competitive Landscape
The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the asthma and COPD drugs market in the U.S. and China. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include GlaxoSmithKline plc, F. Hoffmann-La Roche, AstraZeneca plc, Novartis AG, Boehringer Ingelheim, and Merck and Co., Inc.

The U.S. and China asthma and COPD drugs market has been segmented as follows:

U.S. and China Asthma and COPD Drugs Market, by Drug Class
Bronchodilators 

• Short Acting Beta-2 Agonists
• Long Acting Beta-2 Agonists
• Anti-cholinergic Agents 

Anti-inflammatory Drugs 

• Oral and Inhaled Corticosteroids
• Anti-leukotrienes
• Phosphodiesterase Type-4 Inhibitors
• Others 

Monoclonal Antibodies

Combination Drugs

U.S. and China Asthma and COPD Drugs Market, by Indication

• Asthma
• COPD

Browse More Details @ https://www.researchmoz.us/asthma-and-copd-drugs-market-us-and-china-industry-analysis-size-share-growth-trends-and-forecast-2016-2024-report.html

Increase In Research For The Development Of Asthma Therapeutics In Global Market During The Period 2016 - 2020

Researchmoz added Most up-to-date research on "Increase In Research For The Development Of Asthma Therapeutics In Global Market During The Period 2016 - 2020" to its huge collection of research reports.

Increasing allergic rhinitis is a major factor for allergic asthma leading to increase in research for the development of allergic immunotherapies for the treatment of asthma. The global asthma therapeutics market will observe a moderate growth during the forecast period because of loss of patent exclusivity of the major drugs, allowing the entry of generics into the market. This will lead to the erosion of the market share of the major asthma drugs. However, the presence of late-stage pipeline molecules will drive the market. An increase in the prevalence of asthma and the use of combination drugs will drive the growth of the market during the forecast period.

Technavios analysts forecast the global asthma therapeutics market to grow at a CAGR of 4.31% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global asthma therapeutics market for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the sales of brand-name, generic, and off-label drugs used for the prevention and treatment of asthma. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from patent expiries of marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Asthma Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
AstraZeneca
Boehringer Ingelheim
F. Hoffmann-La Roche
GSK
Merck

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=775675

Other prominent vendors
ALK-Abello
Amgen
Array BioPharma
Asmacure
Astellas Pharma
Atopix Therapeutics
Axikin Pharmaceuticals
Chiesi Farmaceutici
Dynavax Technologies Corp.
Horizon Pharma
Hovione Scientia
Invion
Ivax

Market driver
Huge market potential for mAbs
For a full, detailed list, view our report

Market challenge
Increased preference for CAM
For a full, detailed list, view our report

Market trend
Innovative technologies for drug delivery
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=775675